Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies
- 1 January 1993
- journal article
- clinical trial
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 31 (6) , 423-430
- https://doi.org/10.1007/bf00685030
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer a phase I/II studyCancer, 1990
- Doxorubicin and doxorubicinol: intra-and inter-individual variations of pharmacokinetic parametersCancer Chemotherapy and Pharmacology, 1990
- A dose finding study of prochlorperazine as an antiemetic for cancer chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1989
- Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazineCancer Chemotherapy and Pharmacology, 1989
- Clinical Pharmacology of Continuous Infusion DoxorubicinTherapeutic Drug Monitoring, 1989
- Patterns of anthracycline retention modulation in human tumor cellsCytometry, 1987
- Verapamil Reversal of Clinical Doxorubicin Resistance in Human Cancer A Wilshire Oncology Medical Group Pilot Phase I-II StudyAmerican Journal of Clinical Oncology, 1986
- Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazemMedical and Pediatric Oncology, 1985
- Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide AngiocardiographyNew England Journal of Medicine, 1979
- Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining.The Journal of cell biology, 1975